Island Pharmaceuticals (ASX:ILA) requested a trading halt on the Australian Securities Exchange, pending an update regarding the potential inclusion of its antiviral candidate, galidesivir, in an Ebola clinical trial in Africa, according to a Friday filing with the Australian bourse.
The halt will remain in effect until the earlier of the company releasing the update or the commencement of trading on July 7, the filing added.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.